Advertisement

AAPS PharmSciTech

, Volume 19, Issue 1, pp 155–165 | Cite as

Feasibility of Focused Beam Reflectance Measurement (FBRM) for Analysis of Pharmaceutical Suspensions in Preclinical Development

  • Kaushalkumar DaveEmail author
  • Paul E. LunerEmail author
  • Cecile Forness
  • Doris Baker
  • Corinne Jankovsky
  • Shirlynn Chen
Research Article

Abstract

This study examined the use of focused beam reflectance measurement (FBRM) for qualitative and quantitative analysis of pharmaceutical suspensions with particular application to toxicology supply preparations for use in preclinical studies. Aqueous suspensions of ibuprofen were used as prototype formulations. Initial experiments were conducted to examine the effects of operational conditions including FBRM probe angle, probe location, and mixing (method and rate of mixing) on the FBRM analysis. Once experimental conditions were optimized, the homogeneity and sedimentation-redispersion of particles in the suspensions were assessed. Ibuprofen suspension under continuous agitation was monitored using FBRM for 60 h to study particle size change over time. Another study was performed to determine if particle count rates obtained by FBRM could be correlated to suspension concentration. The location and the angle of the FBRM probe relative to the beaker contents, and the rate and the method of mixing the suspension were found to be sensitive parameters during FBRM analysis. FBRM was able to monitor the process of particle sedimentation in the suspension. The attrition of ibuprofen particles was detectable by FBRM during prolonged stirring with an increase in the number of smaller particles and decrease in the number of larger particles. A strong correlation was observed between particle count rate by FBRM and ibuprofen concentration in the suspension. Also, change in content uniformity in the suspension at different locations of the beaker was represented by FBRM particle count. Overall, FBRM has potential to be a useful tool for qualitative and quantitative analysis of pharmaceutical suspensions.

KEY WORDS

particle size suspension homogeneity and uniformity process analytical technology sedimentation and redispersion preclinical dose formulation 

Notes

Acknowledgements

The authors thank Kevin Shepard of Boehringer Ingelheim for collaboration on the design of the FBRM probe. Also, the authors thank BASF Chemicals for providing the ibuprofen. The authors thank Boehringer Ingelheim Pharmaceuticals, Inc., for supporting this work as a part of Kaushalkumar Dave’s summer internship. The authors thank Anjan Pandey of Mettler Toledo for helpful suggestions for this manuscript.

Compliance with Ethical Standards

Disclaimer

Dr. Kaushalkumar Dave is currently employed at the United States Food and Drug Administration (FDA). This article reflects the views of the authors and should not be construed to represent FDA’s views or policies.

References

  1. 1.
    Neervannan S. Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin Drug Metab Toxicol. 2006;2(5):715–31.CrossRefPubMedGoogle Scholar
  2. 2.
    United States Code of Federal Regulations, Title 21, § 58.113. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=58.113. Accessed 24 Nov. 2016.
  3. 3.
    Smith A, Whitsel M. How to assess preclinical dose formulation homogeneity. Pharm Technol. 2012;36(7):90–1.Google Scholar
  4. 4.
    Whitmire ML, Bryan P, Henry TR, Holbrook J, Lehmann P, Mollitor T, et al. Nonclinical dose formulation analysis method validation and sample analysis. AAPS J. 2010;12(4):628–34.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Barrett P, Glennon B. In-line FBRM monitoring of particle size in dilute agitated suspensions. Part Part Syst Charact. 1999;16(5):207–11.CrossRefGoogle Scholar
  6. 6.
    Schöll J, Kempkes M, Mazzotti M. Focused beam reflectance measurement. In: Chianese A, Kramer HJM, editors. Industrial crystallization process monitoring and control. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2012. doi: 10.1002/9783527645206.ch3
  7. 7.
    Greaves D, Boxall J, Mulligan J, Montesi A, Creek J, Sloan ED, et al. Measuring the particle size of a known distribution using the focused beam reflectance measurement technique. Chem Eng Sci. 2008;63(22):5410–9.CrossRefGoogle Scholar
  8. 8.
    Morris G, Power G, Ferguson S, Barrett M, Hou G, Glennon B. Estimation of nucleation and growth kinetics of benzoic acid by population balance modeling of a continuous cooling mixed suspension, mixed product removal crystallizer. Org Process Res Dev. 2015;19(12):1891–902.CrossRefGoogle Scholar
  9. 9.
    Heinrich J, Ulrich J. Application of laser-backscattering instruments for in situ monitoring of crystallization processes—a review. Chem Eng Technol. 2012;35(6):967–79.Google Scholar
  10. 10.
    Heath AR, Bahri PA, Fawell PD, Farrow JB. Polymer flocculation of calcite: relating the aggregate size to the settling rate. AICHE J. 2006;52(6):1987–94.CrossRefGoogle Scholar
  11. 11.
    Nicu R, Bobu E, Miranda R, Blanco A. Flocculation efficiency of chitosan for papermaking applications. Bioresources. 2012;8(1):768–84.CrossRefGoogle Scholar
  12. 12.
    Whelan J, Murphy E, Pearson A, Jeffers P, Kieran P, McDonnell S, et al. Use of focussed beam reflectance measurement (FBRM) for monitoring changes in biomass concentration. Bioprocess Biosyst Eng. 2012;35(6):963–75.CrossRefPubMedGoogle Scholar
  13. 13.
    Hopfner T, Bluma A, Rudolph G, Lindner P, Scheper T. A review of non-invasive optical-based image analysis systems for continuous bioprocess monitoring. Bioprocess Biosyst Eng. 2010;33(2):247–56.CrossRefPubMedGoogle Scholar
  14. 14.
    Kumar V, Taylor MK, Mehrotra A, Stagner WC. Real-time particle size analysis using focused beam reflectance measurement as a process analytical technology tool for a continuous granulation-drying-milling process. AAPS PharmSciTech. 2013;14(2):523–30.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Zidan AS, Rahman Z, Khan MA. Online monitoring of PLGA microparticles formation using Lasentec focused beam reflectance (FBRM) and particle video microscope (PVM). AAPS J. 2010;12(3):254–62.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Mohammed AR, Weston N, Coombes AG, Fitzgerald M, Perrie Y. Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability. Int J Pharm. 2004;285(1–2):23–34.CrossRefPubMedGoogle Scholar
  17. 17.
    Oldshue JY. Fluid mixing technology and practice. Chem Eng. 1983;90(12):82–108.Google Scholar
  18. 18.
    Sanchez AWM, Smith A. Determining potency of preclinical dose formulations. Pharm Technol. 2012;36(10):132–4.Google Scholar
  19. 19.
    Constantin P, Foias C. Navier-Stokes equations. Chicago: University of Chicago Press; 1988.Google Scholar
  20. 20.
    Heath AR, Fawell PD, Bahri PA, Swift JD. Estimating average particle size by focused beam reflectance measurement (FBRM). Part Part Syst Charact. 2002;19(2):84–95.CrossRefGoogle Scholar
  21. 21.
    Tok AT, Goh X, Ng WK, Tan RB. Monitoring granulation rate processes using three PAT tools in a pilot-scale fluidized bed. AAPS PharmSciTech. 2008;9(4):1083–91.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hamilton P, Littlejohn D, Nordon A, Sefcik J, Slavin P. Validity of particle size analysis techniques for measurement of the attrition that occurs during vacuum agitated powder drying of needle-shaped particles. Analyst. 2012;137(1):118–25.CrossRefPubMedGoogle Scholar
  23. 23.
    Pearson AP, Glennon B, Kieran PM. Monitoring of cell growth using the focused beam reflectance method. J Chem Technol Biotechnol. 2004;79(10):1142–7.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2017

Authors and Affiliations

  • Kaushalkumar Dave
    • 1
    • 2
    Email author
  • Paul E. Luner
    • 1
    Email author
  • Cecile Forness
    • 1
  • Doris Baker
    • 1
  • Corinne Jankovsky
    • 1
  • Shirlynn Chen
    • 1
  1. 1.Material and Analytical SciencesBoehringer Ingelheim Pharmaceuticals, Inc.RidgefieldUSA
  2. 2.Division of Biopharmaceutics, Office of New Drug Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and ResearchFood and Drug AdministrationSilver SpringUSA

Personalised recommendations